Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi‐Stakeholder Think Tank-Reference-Cited by-同舟云学术

Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi‐Stakeholder Think Tank

Published:2018-02-20 Issue:4 Volume:7 Page:
ISSN:2047-9980
Container-title:Journal of the American Heart Association
language:en
Short-container-title:JAHA

Author:

Torok Rachel D.¹,Li Jennifer S.¹,Kannankeril Prince J.²,Atz Andrew M.³,Bishai Raafat⁴,Bolotin Ellen⁵,Breitenstein Stefanie⁵,Chen Cathy⁶,Diacovo Thomas⁷,Feltes Timothy⁸,Furlong Patricia⁹,Hanna Michael¹⁰,Graham Eric M.³,Hsu Daphne¹¹,Ivy D. Dunbar¹²,Murphy Dianne¹³,Kammerman Lisa A.⁴,Kearns Gregory¹⁴,Lawrence John¹⁰,Lebeaut Brigitte⁶,Li Danshi¹⁰,Male Christoph¹⁵,McCrindle Brian¹⁶,Mugnier Pierre¹⁰,Newburger Jane W.¹⁷,Pearson Gail D.¹⁸,Peiris Vasum¹³,Percival Lisa¹⁰,Pina Miriam¹⁹,Portman Ronald²⁰,Shaddy Robert²¹,Stockbridge Norman L.¹³,Temple Robert¹³,Hill Kevin D.¹

Affiliation:

1. Duke University and the Duke Clinical Research Institute, Durham, NC

2. Vanderbilt University Medical Center, Nashville, TN

3. Medical University of South Carolina, Charleston, SC

4. AstraZeneca, Gaithersburg, MD

5. Bayer AG, Whippany, NJ

6. Daiichi Sankyo, Parsippany, NJ

7. Columbia University Medical Center, New York, NY

8. Nationwide Children's Hospital, Columbus, OH

9. Parent Project Muscular Dystrophy, Middletown, OH

10. Bristol‐Myers Squibb, Princeton, NJ

11. Albert Einstein College of Medicine, New York, NY

12. Children's Hospital of Colorado, Aurora, CO

13. US Food and Drug Administration , Silver Spring, MD

14. Arkansas Children's Hospital, Little Rock, AR

15. Medical University of Vienna, Austria

16. University of Toronto, Canada

17. Boston Children's Hospital, Boston, MA

18. US National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

19. Janssen Pharmaceuticals, Raritan, NJ

20. Novartis Pharmaceuticals, East Hanover, NJ

21. Children's Hospital of Los Angeles, CA

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference58 articles.

1. An update on the therapeutic orphan;Wilson JT;Pediatrics,1999

2. Clinical trials in children

3. United States Food and Drug Administration Pediatric Product Development. Available at: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm049867.htm. Accessed June 30 2017.

4. European Medicines Agency Paediatric Regulation. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000068.jsp&mid=WC0b01ac0580925c45. Accessed April 26 2016.

5. Committee on Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA); Board on Health Sciences Policy; Institute of Medicine ; Field MJ Boat TF editors. Safe and Effective Medicines for Children. Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. Washington DC: National Academies Press; 2012.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pediatric Pharmacology for the Primary Care Provider: Advances and Limitations;Pediatrics;2024-06-06

2. Applying Artificial Intelligence in Pediatric Clinical Trials: Potential Impacts and Obstacles;The Journal of Pediatric Pharmacology and Therapeutics;2024-06-01

3. Evaluating registry-based trial economics: Results from the STRESS clinical trial;Contemporary Clinical Trials Communications;2024-04

4. Research Gaps in Pediatric Heart Failure: Defining the Gaps and Then Closing Them Over the Next Decade;Journal of Cardiac Failure;2024-01

5. A point-of-care pharmacokinetic/pharmacodynamic trial in critically ill children: Study design and feasibility;Contemporary Clinical Trials Communications;2023-10